Cargando…

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents

BACKGROUND: Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain dioxygenases, is an oral investigational agent in development for the treatment of anemia secondary to chronic kidney disease. METHODS: In this open-label Phase 2 trial, vadadustat was evaluated in 94 subjec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haase, Volker H, Chertow, Glenn M, Block, Geoffrey A, Pergola, Pablo E, deGoma, Emil M, Khawaja, Zeeshan, Sharma, Amit, Maroni, Bradley J, McCullough, Peter A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322440/ https://www.ncbi.nlm.nih.gov/pubmed/29672740 http://dx.doi.org/10.1093/ndt/gfy055

Ejemplares similares

Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
por: Koury, Mark J., et al.
Publicado: (2022)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO(2)VATE trials
por: Eckardt, Kai-Uwe, et al.
Publicado: (2020)

A phase 3, open‐label, single‐arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis‐stimulating agents
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis
por: Sarnak, Mark J, et al.
Publicado: (2023)

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Treated Patients
por: Parfrey, Patrick S., et al.
Publicado: (2023)

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Naïve Patients
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2023)

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
por: Nguyen, Timothy V., et al.
Publicado: (2011)

Prediction of hemoglobin levels in individual hemodialysis patients by means of a mathematical model of erythropoiesis
por: Fuertinger, Doris H., et al.
Publicado: (2018)

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Hemoglobin response to ferric citrate in patients with nondialysis‐dependent chronic kidney disease and iron deficiency anemia
por: Pergola, Pablo E., et al.
Publicado: (2018)

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism
por: Block, Geoffrey A., et al.
Publicado: (2019)

Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
por: Bernieh, Bassam, et al.
Publicado: (2014)

Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
por: Pirker, Robert, et al.
Publicado: (2012)

Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report
por: Sakurama, Keiki, et al.
Publicado: (2023)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
por: Gupta, Ajay, et al.
Publicado: (2015)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Correction to: Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report
por: Sakurama, Keiki, et al.
Publicado: (2023)

Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease
por: El Hoss, Sara, et al.
Publicado: (2020)

Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study 
por: Gilbertson, David T., et al.
Publicado: (2017)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
por: Jörg, David J., et al.
Publicado: (2023)

Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents
por: Kowalski, Heather, et al.
Publicado: (2023)

Sarcopenia among patients receiving hemodialysis: weighing the evidence
por: Kittiskulnam, Piyawan, et al.
Publicado: (2016)

Effect of hepatitis C virus infection on erythropoiesis in patients on hemodialysis
por: Saifan, Chadi, et al.
Publicado: (2013)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

Lessons for Medicare Part D in the hemodialysis community
por: Nayeem, Anisa I, et al.
Publicado: (2006)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells
por: Zielniok, Katarzyna, et al.
Publicado: (2020)

Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
por: Xiong, Limei, et al.
Publicado: (2022)

THE RELATIONSHIP BETWEEN RNA SYNTHESIS AND HEMOGLOBIN SYNTHESIS IN AMPHIBIAN ERYTHROPOIESIS : Cytochemical Evidence
por: Grasso, Joseph A., et al.
Publicado: (1966)

THE EFFECT OF HEMOGLOBIN INJECTIONS ON ERYTHROPOIESIS AND ERYTHROCYTE SIZE IN RABBITS RENDERED ANEMIC BY BLEEDING
por: Miller, D. K., et al.
Publicado: (1934)

The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients
por: Kwon, Owen, et al.
Publicado: (2015)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease
por: Chertow, Glenn M., et al.
Publicado: (2017)

Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults
por: Paulson, Susan K., et al.
Publicado: (2022)

Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
por: Won, Hye Sung, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7qjlns3po66t6g5b0i58jphub1